Lindsay Fischer is an editor at ONN. She specializes in healthcare topics, particularly focusing on nursing, cancer treatment, drug approvals, and treatment strategies. Lindsay has been featured in Targeted Oncology, Cancer Network, CURE Media Group, OncLive, Oncology Nursing News, and Wiley.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Lindsay Fischer's consistent coverage of healthcare and pharmaceutical topics, with a focus on data-driven insights and expert commentary, indicates that she is likely to be responsive to pitches offering in-depth analysis or interviews from reputable experts in the field. With a strong emphasis on citing data, providing evidence-based research or access to credible sources will enhance the chances of effective outreach.
As Lindsay does not have a specified geographic focus, pitches should address international developments within healthcare and pharmaceuticals. Additionally, given her frequent use of press releases as content sources, organizations promoting new studies or drug approvals may find success by sharing their latest findings for potential coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Click on the article title to read more.
Lindsay Fischer | Authors | Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient-centered cancer care.
With a new approval for elacestrant, patients with ER+/HER2–, ESR1-mutated metastatic breast cancer have an oral alternative to fulvestrant.
